Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

payer survey

- PMLiVE

Men’s Health Week: The Power of Conversation

We're launching a number of schemes to help support men's mental health throughout the year. This Men's Health Week, make sure you check out some of our plans.

Mednet Group

Maximizing KOL Engagement with Asynchronous Tools

Dive into the variety of asynchronous tools available on the Impetus InSite Platform® with our ninth tip. Learn how different tools can enhance your virtual touchpoints and elevate the quality...

Impetus Digital

- PMLiVE

AstraZeneca’s Farxiga granted FDA approval to treat type 2 diabetes in paediatric patients

The chronic disease currently affects almost 30,000 people aged under 20 years in the US

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shows promise in fatty liver disease MASH

Metabolic dysfunction-associated steatohepatitis is the second most common contributor to liver transplantation in the US

- PMLiVE

GSK and Ochre Bio enter multi-year partnership to investigate liver disease drivers

There are more than 10,000 deaths due to liver disease each year in the UK

- PMLiVE

MIT protein study could help accelerate development of new antibiotics

Histidine kinase is a crucial bacterial protein that regulates processes, including antibiotic resistance

- PMLiVE

Ipsen’s Iqirvo receives FDA approval to treat adults with primary biliary cholangitis

The rare cholestatic liver disease currently affects approximately 100,000 people in the US

- PMLiVE

J&J agrees $700m settlement with US states to resolve talcum powder claims

The company has ended global sales of the affected products in favour of cornstarch versions

- PMLiVE

UCB’s Bimzelx granted MHRA approval to treat hidradenitis suppurativa in adults

The authorisation applies to patients who have had an inadequate response to conventional systemic HS therapy

- PMLiVE

Sanofi/Regeneron’s Kevzara approved by FDA for polyarticular juvenile idiopathic arthritis

The chronic disease is designated as one of the three major types of juvenile idiopathic arthritis

EU flag

EMA announces launch of two advice pilots to improve clinical trials in Europe

The pilots are part of the Accelerating Clinical Trials in the EU initiative to foster high-quality clinical research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links